Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Albshesh, Ahmad, Taylor, Joshua, Savarino, Edoardo V., Truyens, Marie, Armuzzi, Alessandro, Ribaldone, Davide G., Shitrit, Ariella Bar-Gil, Fibelman, Morine, Molander, Pauliina, Liefferinckx, Claire, Nancey, Stephane, Korani, Mohamed, Rutka, Mariann, Barreiro-de Acosta, Manuel, Domislovic, Viktor, Suris, Gerard, Eriksson, Carl, Alves, Catarina, Mpitouli, Afroditi, di Jiang, Caroline, Tepeš, Katja, Coletta, Marina, Foteinogiannopoulou, Kalliopi, Gisbert, Javier P., Amir-Barak, Hadar, Attauabi, Mohamed, Seidelin, Jakob, Afif, Waqqas, Marinelli, Carla, Lobaton, Triana, Pugliese, Daniela, Maharshak, Nitsan, Cremer, Anneline, Limdi, Jimmy K., Molnár, Tamás, Otero-Alvarin, Borja, Krznaric, Zeljko, Magro, Fernando, Karmiris, Konstantinos, Raine, Tim, Drobne, David, Koutroubakis, Ioannis, Chaparro, Maria, Yanai, Henit, Burisch, Johan, Kopylov, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268494/
https://www.ncbi.nlm.nih.gov/pubmed/34209880
http://dx.doi.org/10.3390/jcm10132914
Descripción
Sumario:Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

Ejemplares similares